Evidence map›Paper›PMID 28835816›Full record

ArticleJournal of tissue engineering

A quantitative, multi-national and multi-stakeholder assessment of barriers to the adoption of cell therapies.

Benjamin M Davies, James Smith, Sarah Rikabi, Karolina Wartolowska, Mark Morrey, Anna French, Robert MacLaren, David Williams, Kim Bure, Rafael Pinedo-Villanueva and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of tissue engineering. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Benjamin M DaviesDivision of Trauma and Orthopaedic Surgery, Department of Surgery, University of Cambridge, Cambridge, UK.
James SmithThe UCL-Oxford Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK.
Sarah RikabiNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Karolina WartolowskaNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Mark MorreyDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.
Anna FrenchThe UCL-Oxford Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK.
Robert MacLarenNuffield Laboratory of Ophthalmology, University of Oxford, Oxford, UK.
David WilliamsCentre for Biological Engineering, The Wolfson School of Mechanical, Electrical and Manufacturing Engineering, Loughborough University, Loughborough, UK.
Kim BureSartorius Stedim, Göttingen, Germany.
Rafael Pinedo-VillanuevaNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.
Anthony MathurNIHR Cardiovascular Biomedical Research Unit, London Chest Hospital, London, UK.
Martin BirchallRoyal National Throat, Nose, and Ear Hospital, University College London, London, UK.
Evan SnyderSanford Burnham Prebys Medical Discovery Institute, San Diego, CA, USA.
Anthony AtalaWake Forest Institute for Regenerative Medicine, Winston-Salem, NC, USA.
Brock ReeveHarvard Stem Cell Institute, Cambridge, MA, USA.
David BrindleyThe UCL-Oxford Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK.

Funding

Medical Research Council G1001539Medical Research Council MR/K026453/1
6 · The paper itself

Abstract

Cellular therapies, such as stem cell-based treatments, have been widely researched and numerous products and treatments have been developed. Despite this, there has been relatively limited use of these technologies in the healthcare sector. This study sought to investigate the perceived barriers to this more widespread adoption. An anonymous online questionnaire was developed, based on the findings of a pilot study. This was distributed to an audience of clinicians, researchers and commercial experts in 13 countries. The results were analysed for all respondents, and also sub-grouped by geographical region, and by profession of respondents. The results of the study showed that the most significant barrier was manufacturing, with other factors such as efficacy, regulation and cost-effectiveness being identified by the different groups. This study further demonstrates the need for these important issues to be addressed during the development of cellular therapies to enable more widespread adoption of these treatments.

Indexed as

Cell- and tissue-based therapyclinical adoptionregenerative medicinestem cellstranslational medical research

Identifiers

PMID28835816
PMCPMC5557158

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.